engleski

From the Cochrane Library: Interventions for pityriasis rosea

Pityriasis rosea (PR) is a benign self-limited rash that presents as multiple erythematous patches on the trunk and limbs. While the exact etiology of PR remains unknown, human herpesviruses 6 and 7 have been implicated in its pathogenesis. PR treatment is centered on relieving symptoms, however, no standardized treatment exists for PR. A 2019 Cochrane review provided a comprehensive analysis of the efficacy and safety of available PR treatments that have been studied in randomized controlled trials (RCTs). This review analyzed 14 parallel RCTs and assessed 2 primary outcomes: good or excellent rash improvement within 2 weeks (participant-rated) and serious adverse events. Secondary outcomes were also measured, including resolution of itch within 2 weeks (participant-rated), and good or excellent rash improvement within 2 weeks (provider-rated). Two RCTs found significant provider-rated rash improvement with acyclovir compared to placebo and vitamins or when used in addition to a topical regimen. However, the trials employed varying doses of acyclovir, and the review was unable to recommend a specific dose for PR treatment.

acyclovir ; erythromycin ; itch ; pityriasis rosea ; rash ; systematic review

nije evidentirano